FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer

被引：0

作者：

Moore, K. N. ^{[1
]}

Vergote, I. ^{[2
]}

Oaknin, A. ^{[3
]}

Colombo, N. ^{[4
]}

Banerjee, S. ^{[5
]}

Oza, A. M. ^{[6
]}

Pautier, P. ^{[7
]}

Kelly, C. M. ^{[8
]}

Malek, K. ^{[9
]}

Birrer, M. J. ^{[10
]}

机构：

[1] Univ Oklahoma, Stephenson Canc Ctr, Obstet & Gynecol, Oklahoma City, OK USA

[2] Univ Hosp Leuven, Gynaecol Verloskunde, Leuven, Belgium

[3] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain

[4] Ist Europeo Oncol, Dept Gynecol Oncol, Milan, Italy

[5] Royal Marsden, Gynaecol Unit, London, England

[6] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[7] Gustave Roussy Inst Cancerol, Med Oncol, Villejuif, France

[8] Univ Coll Dublin, Mater Misericordiae Univ Hosp, Med Oncol, Dublin, Ireland

[9] ImmunoGen Inc, Clin Dev, Waltham, MA USA

[10] Massachusetts Gen Hosp, Gynecol Oncol, Boston, MA 02114 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

991TiP

引用

页数：1